Literature DB >> 23735006

Constrained H-Phe-Phe-NH2 analogues with high affinity to the substance P 1-7 binding site and with improved metabolic stability and cell permeability.

Rebecca Fransson1, Christian Sköld, Jadel M Kratz, Richard Svensson, Per Artursson, Fred Nyberg, Mathias Hallberg, Anja Sandström.   

Abstract

We recently reported the discovery of H-Phe-Phe-NH2 as a small and high affinity ligand for the substance P 1-7 (SP(1-7), H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-OH) specific binding site and its intriguing ability to reduce neuropathic pain. With the overall aim to develop stable and orally bioavailable SP(1-7) mimetics, the dipeptide was chosen as a lead compound. Herein the structure-activity relationship (SAR) of a set of modified H-Phe-Phe-NH2 analogues is presented together with their potential active uptake by PEPT1 transporter, intestinal permeability, and metabolic stability. Local constraints via peptide backbone methylation or preparation of cyclized analogues based on pyrrolidine were evaluated and were shown to significantly improve the in vitro pharmacokinetic properties. The SAR was rationalized by deriving a plausible binding pose for the high affinity ligands. Rigidification using a 3-phenylpyrrolidine moiety in the C-terminal of H-Phe-Phe-NH2 resulted in high affinity and improved intrinsic clearance and intestinal epithelial permeability.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23735006     DOI: 10.1021/jm400209h

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Exploration and pharmacokinetic profiling of phenylalanine based carbamates as novel substance p 1-7 analogues.

Authors:  Rebecca Fransson; Gunnar Nordvall; Johan Bylund; Anna Carlsson-Jonsson; Jadel M Kratz; Richard Svensson; Per Artursson; Mathias Hallberg; Anja Sandström
Journal:  ACS Med Chem Lett       Date:  2014-10-29       Impact factor: 4.345

2.  Synthesis and Preclinical Evaluation of the First Carbon-11 Labeled PET Tracers Targeting Substance P1-7.

Authors:  Aleksandra Pekošak; Janez Ž Bulc; Špela Korat; Robert C Schuit; Esther Kooijman; Ricardo Vos; Marissa Rongen; Mariska Verlaan; Kevin Takkenkamp; Wissam Beaino; Alex J Poot; Albert D Windhorst
Journal:  Mol Pharm       Date:  2018-10-25       Impact factor: 4.939

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.